Morphometric analysis of nuclear shape irregularity as a novel predictor of programmed death-ligand 1 expression in lung squamous cell carcinoma-Reference-Cited by-同舟云学术

Morphometric analysis of nuclear shape irregularity as a novel predictor of programmed death-ligand 1 expression in lung squamous cell carcinoma

Published:2023-05-12 Issue: Volume: Page:
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Saito-Koyama Ryoko^ORCID,Tamai Keiichi,Yasuda Jun,Okamura Yasunobu,Yamazaki Yuto,Inoue Chihiro,Miki Yasuhiro,Abe Jiro,Oishi Hisashi,Sato Ikuro,Sasano Hironobu

Funder

JSPS KAKENHI

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00428-023-03548-z.pdf

Reference44 articles.

1. Adib E, Nassar AH, Abou Alaiwi S, Groha S, Akl EW, Sholl LM, Michael KS, Awad MM, Jnne PA, Gusev A, Kwiatkowski DJ (2022) Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology. Genome Med 14:39. https://doi.org/10.1186/s13073-022-01041-x

2. Tan AC, Tan DSW (2022) Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 40:611–625. https://doi.org/10.1200/JCO.21.01626

3. Santos ES, Rodriguez E (2022) Treatment considerations for patients with advanced squamous cell carcinoma of the lung. Clin Lung Cancer 23:457–466. https://doi.org/10.1016/j.cllc.2022.06.002

4. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7

5. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092. https://doi.org/10.1056/NEJMoa1801005